Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPD-HF: Tiotropium/Olodaterol in Chronic Heart Failure Patients with COPD
jRCTs051200057Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tiotropium + olodaterol in chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF), sponsored by Boehringer Ingelheim. Primary endpoint: Improvement of plasma BNP levels at 12 weeks. Started Mar 2021; status: active, not recruiting.
02
Drugs
tiotropium + olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic heart failure (CHF)
Beyond the preview
Go deeper on jRCTs051200057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200057.